MEFLOQUINE HYDROCHLORIDE (mefloquine hydrochloride) by Medica Corp is clinical pharmacology pharmacokinetics absorption: the absolute oral bioavailability of mefloquine has not been determined since an intravenous formulation is not available. Approved for mild to moderate acute malaria caused by mefloquine-susceptible strains of p. First approved in 1989.
Drug data last refreshed 13h ago · AI intelligence enriched 3w ago
Mefloquine hydrochloride is an oral antimalarial agent approved in 1989 that acts as a blood schizonticide against erythrocytic stages of Plasmodium species. It is used to treat mild to moderate acute malaria caused by mefloquine-susceptible strains, including chloroquine-resistant P. falciparum. The drug's exact mechanism of action remains incompletely understood, though it demonstrates activity against multiple malaria parasite species.
As LOE approaches, the brand team is likely contracting; opportunities focus on defensive positioning and generic transition planning rather than growth initiatives.
CLINICAL PHARMACOLOGY Pharmacokinetics Absorption: The absolute oral bioavailability of mefloquine has not been determined since an intravenous formulation is not available. The bioavailability of the tablet formation compared with an oral solution was over 85%. The presence of food significantly…
Worked on MEFLOQUINE HYDROCHLORIDE at Medica Corp? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Working on mefloquine offers limited growth career trajectory but valuable expertise in mature-market management, global health strategy, and developing-market operations. Roles emphasize cost containment, competitive defense, and international market dynamics rather than launch excitement or innovation-phase responsibilities.